The Apex Times
Above the Noise
Business Wire
BusinessLilly shares early Phase 1 findings for FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer at ESMO 2026The Apex TimesBusinessChina’s incremental market-access move reignites attention on global payment networks like MastercardThe Apex TimesBusinessLockheed Martin’s lower valuation versus RTX draws investor comparison, as defense spending remains a key tailwindThe Apex TimesBusinessOpinion piece pits Nvidia against TSMC for a single, five-year AI betThe Apex TimesBusinessNike approves Genon AI system to automate outsole defect checks, rollout planned for 2027The Apex TimesBusinessBroadcom options market shows outsized appetite for a $600-call bet as “AI fears” enter the debateThe Apex TimesBusinessAmazon buys 3M products for data centers, a move analysts say could ripple across the marketThe Apex TimesBusinessBooz Allen Hamilton shares catch a bid after earnings beat and higher full-year adjusted outlookThe Apex TimesBusinessPalantir expands “sovereign AI” push, betting that controlled deployment wins enterprise and government buyersThe Apex TimesBusinessNVIDIA chief Jensen Huang counters the memory-bear narrative as investors rush to reprice AI hardware timelinesThe Apex TimesBusinessElon Musk argues Tesla’s customer demand is driven by Full Self-Driving, not car-by-car specsThe Apex TimesBusinessCostco starts selling an AI smartphone gimbal on member-only shelves, indicating a new push into camera techThe Apex TimesBusinessLilly shares early Phase 1 findings for FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer at ESMO 2026The Apex TimesBusinessChina’s incremental market-access move reignites attention on global payment networks like MastercardThe Apex TimesBusinessLockheed Martin’s lower valuation versus RTX draws investor comparison, as defense spending remains a key tailwindThe Apex TimesBusinessOpinion piece pits Nvidia against TSMC for a single, five-year AI betThe Apex TimesBusinessNike approves Genon AI system to automate outsole defect checks, rollout planned for 2027The Apex TimesBusinessBroadcom options market shows outsized appetite for a $600-call bet as “AI fears” enter the debateThe Apex TimesBusinessAmazon buys 3M products for data centers, a move analysts say could ripple across the marketThe Apex TimesBusinessBooz Allen Hamilton shares catch a bid after earnings beat and higher full-year adjusted outlookThe Apex TimesBusinessPalantir expands “sovereign AI” push, betting that controlled deployment wins enterprise and government buyersThe Apex TimesBusinessNVIDIA chief Jensen Huang counters the memory-bear narrative as investors rush to reprice AI hardware timelinesThe Apex TimesBusinessElon Musk argues Tesla’s customer demand is driven by Full Self-Driving, not car-by-car specsThe Apex TimesBusinessCostco starts selling an AI smartphone gimbal on member-only shelves, indicating a new push into camera techThe Apex TimesBusinessLilly shares early Phase 1 findings for FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer at ESMO 2026The Apex TimesBusinessChina’s incremental market-access move reignites attention on global payment networks like MastercardThe Apex TimesBusinessLockheed Martin’s lower valuation versus RTX draws investor comparison, as defense spending remains a key tailwindThe Apex TimesBusinessOpinion piece pits Nvidia against TSMC for a single, five-year AI betThe Apex TimesBusinessNike approves Genon AI system to automate outsole defect checks, rollout planned for 2027The Apex TimesBusinessBroadcom options market shows outsized appetite for a $600-call bet as “AI fears” enter the debateThe Apex TimesBusinessAmazon buys 3M products for data centers, a move analysts say could ripple across the marketThe Apex TimesBusinessBooz Allen Hamilton shares catch a bid after earnings beat and higher full-year adjusted outlookThe Apex TimesBusinessPalantir expands “sovereign AI” push, betting that controlled deployment wins enterprise and government buyersThe Apex TimesBusinessNVIDIA chief Jensen Huang counters the memory-bear narrative as investors rush to reprice AI hardware timelinesThe Apex TimesBusinessElon Musk argues Tesla’s customer demand is driven by Full Self-Driving, not car-by-car specsThe Apex TimesBusinessCostco starts selling an AI smartphone gimbal on member-only shelves, indicating a new push into camera techThe Apex TimesBusinessLilly shares early Phase 1 findings for FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer at ESMO 2026The Apex TimesBusinessChina’s incremental market-access move reignites attention on global payment networks like MastercardThe Apex TimesBusinessLockheed Martin’s lower valuation versus RTX draws investor comparison, as defense spending remains a key tailwindThe Apex TimesBusinessOpinion piece pits Nvidia against TSMC for a single, five-year AI betThe Apex TimesBusinessNike approves Genon AI system to automate outsole defect checks, rollout planned for 2027The Apex TimesBusinessBroadcom options market shows outsized appetite for a $600-call bet as “AI fears” enter the debateThe Apex TimesBusinessAmazon buys 3M products for data centers, a move analysts say could ripple across the marketThe Apex TimesBusinessBooz Allen Hamilton shares catch a bid after earnings beat and higher full-year adjusted outlookThe Apex TimesBusinessPalantir expands “sovereign AI” push, betting that controlled deployment wins enterprise and government buyersThe Apex TimesBusinessNVIDIA chief Jensen Huang counters the memory-bear narrative as investors rush to reprice AI hardware timelinesThe Apex TimesBusinessElon Musk argues Tesla’s customer demand is driven by Full Self-Driving, not car-by-car specsThe Apex TimesBusinessCostco starts selling an AI smartphone gimbal on member-only shelves, indicating a new push into camera techThe Apex Times
Back to front
Johnson & Johnson starts commercial rollout in Europe of dual-energy cardiac ablation catheter
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 1, 5:52 PM EDT

Johnson & Johnson starts commercial rollout in Europe of dual-energy cardiac ablation catheter

Johnson & Johnson said it has launched a Dual Energy THERMOCOOL SMARTTOUCH SF ablation catheter in Europe, indicating continued investment in cardiology device offerings as it expands access to heart-rhythm treatment tools.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Johnson & Johnson has begun the commercial rollout in Europe of a catheter used for cardiac ablation, the company said in a late June update carried by Yahoo Finance. The announcement centers on the Dual Energy THERMOCOOL SMARTTOUCH SF (DE THERMOCOOL SMARTTOUCH SF) catheter, a product line associated with ablation procedures intended to treat certain heart-rhythm disorders.

According to the report, the launch follows Johnson & Johnson’s decision to make the “dual-energy” version of the THERMOCOOL SMARTTOUCH SF catheter available to European customers. The update described it as a commercial launch, not a pilot or study phase.

The report does not spell out regulatory milestones, country-by-country approvals, or the specific performance or workflow characteristics of the dual-energy design. It also does not disclose pricing, reimbursement expectations, or competitive positioning versus other catheter systems used for ablation in Europe.

Johnson & Johnson’s cardiology device efforts typically sit alongside its broader medical-technology portfolio, which includes products used in electrophysiology, cardiovascular surgery, and other procedure-based specialties. A new catheter launch can matter commercially because ablation procedures are device-driven and recurring in nature, with hospitals often making long-term purchasing decisions for procedure kits and catheter platforms.

Market reaction and adoption timing, however, are not directly addressed in the article. The post does not provide any quantified sales impact, forecast ranges, or early uptake metrics from European centers, leaving investors to wait for later disclosures that could show whether demand ramps as quickly as the initial launch suggests.

For now, what appears clear from the reporting is that Johnson & Johnson is using a steady cadence of device releases to broaden its electrophysiology offerings in Europe, with the dual-energy THERMOCOOL SMARTTOUCH SF catheter as the headline product.

The company’s announcement, as reflected in the Yahoo Finance write-up, leaves several practical questions unanswered for clinicians and buyers, including where the product is first available across European markets and what, if any, training or procedural protocols are required for routine use. Those details, if not yet public in the cited post, may be released separately through regulatory and customer channels.

Why It Matters

  • Expanding catheter options can influence hospital procurement decisions in electrophysiology, where device selection is tightly linked to procedure volumes and clinician preferences.
  • A Europe commercial launch suggests Johnson & Johnson is continuing to compete for market share in cardiac ablation amid active rival device portfolios.
  • Without disclosed commercial metrics, near-term financial impact is uncertain, making future company communications important for investors.
  • For clinicians, the availability of a dual-energy catheter may support attempts to optimize ablation procedures, but the reported coverage does not describe the clinical or technical differences in detail.

Sources

Key Facts

  • Johnson & Johnson said it launched the Dual Energy THERMOCOOL SMARTTOUCH SF (DE THERMOCOOL SMARTTOUCH SF) cardiac ablation catheter for commercial use in Europe.
  • The launch was announced on June 25, as reported by Yahoo Finance.
  • The product is described in the report as a dual-energy variation within the THERMOCOOL SMARTTOUCH SF catheter family.
  • The cited coverage does not provide Europe-by-Europe approval details, pricing, or reimbursement information.
  • No sales forecasts, early adoption metrics, or quantified commercial impact were included in the reported update.

Healthcare Related